American Journal of Respiratory and Critical Care Medicine · 2021 · 37 citations · 7 references
PharmacyPharmacologyPharmacotherapyAntimicrobial PharmacotherapyAntimicrobial ResistanceTuberculosis ControlAntibiotic ResistanceDrug ResistanceMultidrug ResistanceTuberculosis CareTuberculosis EpidemiologyTuberculosis PharmacotherapyConfidence Intervals For Odds RatiosDrug Resistance Pattern AnalysisDrug Resistance TestingExtensively Drug-resistant Tuberculosis TreatmentFluoroquinolone-based RegimensLogistic RegressionMultidrug-resistant Tuberculosis TreatmentTuberculosis Drug Resistance
Abstract Rationale Until 2020, extensively drug-resistant tuberculosis (XDR-TB) was defined as TB with resistance to rifampicin and isoniazid (multidrug-resistant TB [MDR-TB]), any fluoroquinolone (FQ), and any second-line injectable drug (SLID). In 2019, the World Health Organization issued new recommendations for treating patients with drug-resistant TB, substantially limiting the role of SLIDs in MDR-TB treatment and thus putting the definition of XDR-TB into question. Objectives To propose an up-to-date definition for XDR-TB. Methods We used a large data set to assess treatment outcomes for patients with MDR-TB exposed to any type of longer regimen. We included patients with bacteriologically confirmed MDR-TB and known FQ and SLID resistance results. We performed logistic regression to estimate the adjusted odds ratios (aORs) for an unfavorable treatment outcome (failure, relapse, death, loss to follow-up), and estimates were stratified by the resistance pattern (FQ and/or SLID) and group A drug use (moxifloxacin/levofloxacin, linezolid, and/or bedaquiline). Measurements and Main Results We included 11,666 patients with MDR-TB; 4,653 (39.9%) had an unfavorable treatment outcome. Resistance to FQs increased the odds of an unfavorable treatment outcome (aOR, 1.91; 95% confidence interval [CI], 1.63–2.23). Administration of bedaquiline and/or linezolid improved treatment outcomes regardless of resistance to FQs and/or SLIDs. Among patients with XDR-TB, compared with persons receiving no group A drug, aORs for an unfavorable outcome were 0.37 (95% CI, 0.20–0.69) with linezolid only, 0.40 (95% CI, 0.21–0.77) with bedaquiline only, and 0.21 (95% CI, 0.12–0.38) with both. Conclusions Our study supports a new definition of XDR-TB as MDR-TB and additional resistance to FQ plus bedaquiline and/or linezolid and helps assess the adequacy of this definition for surveillance and treatment choice.
7
Norbert Ndjeka, Kathryn Schnippel, Iqbal Master et al. · European Respiratory Journal · 2018 · 134 citations · Full text
J. Peter Cegielski, Ekaterina V. Kurbatova, Martie van der Walt et al. · Clinical Infectious Diseases · 2015 · 101 citations · Full text
Life Sciences, Pharmacology, Antimicrobial Pharmacotherapy +14
The survival of sputum-positive consumptives
W. H. Tattersall · Tubercle · 1947 · 29 citations